Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR) will release topline data from its ACCESS clinical program of aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist for obesity, before market open on Monday, December 8, 2025. Management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.
Investors can access the live webcast via the company Investor Relations events page and obtain phone dial-in details from the provided link. A replay will be posted approximately two hours after the live event and will remain available for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – GPCR
In the Dec 8 session, GPCR gained 102.49%, reflecting a significant positive market reaction. Argus tracked a peak move of +156.5% during that session. Argus tracked a trough of -32.5% from its starting point during tracking. Our momentum scanner triggered 91 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 7.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings update | Positive | +3.9% | Reaffirmed ACCESS data timing and strong cash balance through at least 2027. |
| Sep 02 | Investor conferences | Positive | +4.0% | Announced participation in major healthcare investor conferences with webcasts. |
| Aug 06 | Earnings update | Negative | -0.7% | Higher R&D spend and larger net loss while advancing oral obesity pipeline. |
| Jun 20 | Clinical data | Positive | +1.7% | New preclinical data for oral amylin agonist and GLP-1 candidate at ADA meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across recent earnings, conference, and clinical updates, GPCR’s share price has consistently moved in the same direction as the apparent news tone, with no recorded divergences.
This announcement fits into a sequence of catalyst-focused updates for aleniglipron and the obesity portfolio. On Aug 06, 2025 and Nov 06, 2025, earnings reports highlighted strong cash positions of $786.5M and $799.0M and reaffirmed plans for ACCESS topline data by year-end 2025. A Jun 20, 2025 clinical update showcased positive preclinical data for ACCG-2671 and GSBR-5595, while a Sep 02, 2025 conference notice underscored growing investor outreach. Today’s scheduling of the ACCESS topline readout is the next step in that clearly signposted catalyst path.
Key Terms
glp-1 receptor agonist medical
topline data technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company’s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.
To access the live webcast, please visit the Investor Relations page of the company’s website at https://ir.structuretx.com/events-presentations/events. To access the call by phone, participants should visit this link to receive dial-in details. The webcast will be made available for replay on the company's website beginning approximately two hours after the live event. The replay of the webcast will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
